| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
ImmunityBio, Inc.
13D/A
IBRX · 45256X103
|
64.8% |
8/6/2026
Event 7/31/2026
|
||||
| Cambridge Equities, LP | 24.7% | |||||
| MP 13 Ventures, LLC | 24.7% | |||||
| NantWorks, LLC | 9.3% | |||||
| Nant Capital, LLC | 29.6% | |||||
| California Capital Equity, LLC | 10.0% | |||||
| Patrick Soon-Shiong | 64.8% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.